ERBB2 and breast carcinoma: Our results predict that MAPK pathway-activating mutations (such as KRASG12V) may be genetic mechanisms of resistance to HER2-direted therapy in indications outside of breast cancer, with higher EGFR and lower ERBB3 and CDKN1B expression [32].